Acquisitions help public companies diversify their portfolios and revenue streams while providing private companies access to more financing. Public companies such as SinglePoint, Inc. (OTC: SING) (SING Profile), Vinergy Resources Ltd. (OTC: VNNYF) and ChineseInvestors.com, Inc. (OTC: CIIX) have already initiated or completed such acquisitions, encouraged by the significant growth potential that cannabis-based product manufacturing businesses bring to the table.
This impressive potential is perfectly exemplified by GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharma company focused on developing cannabinoid prescription medicines.
With a reputation as the world's largest company involved in the production and commercialization of cannabis-based therapeutics, GW Pharmaceuticals (NASDAQ: GWPH) has operations in Europe, Canada, the United States and Asia. Based on its proprietary cannabinoid product platform, GW Pharma has developed therapies for the treatment of various conditions, including multiple sclerosis-related spasticity and neuropathic pain.
Its product pipeline is also targeting tuberculosis sclerosis complex, infantile spasms, adult epilepsy, schizophrenia and more. But GW Pharma is one of the few developers of cannabis-based products or therapies that are publicly traded, given the legal hurdles and the lingering public misconceptions facing the industry.
This is why a large number of growers, dispensaries and product companies choose to operate privately or to be acquired by other public companies with interests in the industry. As a $3 billion company, GW Pharmaceuticals is a prime example of the massive potential cannabis offers the public market.
For the full story go to Bio-Medicine